Microwave ablation combined with anti-LAG-3 therapy enhances anti-tumor immunity in hepatocellular carcinoma mice by regulating CXCL10/CXCR3-mediated CD8+ T cell activation
Cancer Immunology, Immunotherapy · 18.08.2026 · 75 (11)
DOI: 10.1007/s00262-026-04523-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 18.08.2026. Verfasst von Zhilan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Third, Xiangya Hospital of Central South University, Hunan Province, Changsha, 410013, People's Republic of China. Hauptthemen laut MEDLINE: Chemokine CXCL10, Receptors, CXCR3, Liver Neoplasms, CD8-Positive T-Lymphocytes. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hainan Province.
Abstract (Originalsprache)
Background
The therapeutic potential of combining microwave ablation (MWA) with lymphocyte-activation gene 3 (LAG-3) blockade has been demonstrated in various cancers, while its specific efficacy and molecular mechanisms in hepatocellular carcinoma (HCC) remain unclear.
Methods
LAG-3 expression in clinical samples was investigated. LAG-3 expression in tumor-infiltrating lymphocytes (TILs) was further explored using HCC-bearing mice treated with MWA. Moreover, the survival rate, tumor growth, TIL recruitment, and CD8 + T cell function were monitored in mice treated with MWA and LAG-3 blockade. Further CXCL10 blockade or CD8 blockade strategies were employed to elucidate the underlying mechanisms of the anti-tumor immunity.
Results
LAG-3, CXCL10, CXCR3, and CD8 were highly expressed in human HCC tissues. MWA treatment elevated LAG-3 expression in subsets of TILs. In contrast to MWA or anti-LAG-3 therapy alone, the combination of MWA and anti-LAG-3 therapy exhibited a synergistic effect, resulting in prolonged survival, inhibited tumor growth, increased infiltration of TILs, elevated serum CXCL10 level, an enhanced population of CXCR3 + CD8 + T cells, and increased CD8 + T cell cytotoxic activity in HCC-bearing mice. Furthermore, blockade of CXCL10 weakened the CD8 + T cell function in the combined therapy group. Additionally, CD8 blockade promoted tumor growth and impaired CD8 + T cell function under the combined treatment.
Conclusion
MWA combined LAG-3 blockade emerged as a distinctive therapeutic approach for HCC, and the underlying mechanism is rooted in the CXCL10/CXCR3-mediated activation of CD8 + T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Third, Xiangya Hospital of Central South University, Hunan Province, Changsha, 410013, People's Republic of China.
- Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Hainan Province, Haikou, 570208, People's Republic of China.
- The Third, Xiangya Hospital of Central South University, Hunan Province, Changsha, 410013, People's Republic of China. zhouping1000@hotmail.com.
Förderung
- Natural Science Foundation of Hainan Province
Zitieren
APA
Zhang, Z., Zhang, J., Wei, S., Fu, Y., Li, Z., Zhang, W., Xin, M., & Zhou, P. (2026). Microwave ablation combined with anti-LAG-3 therapy enhances anti-tumor immunity in hepatocellular carcinoma mice by regulating CXCL10/CXCR3-mediated CD8+ T cell activation. Cancer Immunology, Immunotherapy, 75(11). https://doi.org/10.1007/s00262-026-04523-8
Vancouver
Zhang Z, Zhang J, Wei S, Fu Y, Li Z, Zhang W, et al. Microwave ablation combined with anti-LAG-3 therapy enhances anti-tumor immunity in hepatocellular carcinoma mice by regulating CXCL10/CXCR3-mediated CD8+ T cell activation. Cancer Immunology, Immunotherapy. 2026;75(11). doi:10.1007/s00262-026-04523-8
BibTeX
@article{Zhang2026,
author = {Zhang, Zhilan and Zhang, Jiangshan and Wei, Shan and Fu, Yeliu and Li, Zhongju and Zhang, Weifang and Xin, Minhui and Zhou, Ping},
title = {Microwave ablation combined with anti-LAG-3 therapy enhances anti-tumor immunity in hepatocellular carcinoma mice by regulating CXCL10/CXCR3-mediated CD8+ T cell activation},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
volume = {75},
number = {11},
doi = {10.1007/s00262-026-04523-8}
}
EUVIMED